NCT01124435View on ClinicalTrials.gov

Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

September 30, 2007

Study Completion Date

December 31, 2008

Conditions
Ovarian Neoplasms
Interventions
DRUG

Carboplatin plus Celecoxib

celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days).

Trial Locations (1)

00168

Department of Obstetrics and Gynecology,Catholic University, Rome, Italy, Rome

All Listed Sponsors
lead

Catholic University of the Sacred Heart

OTHER

NCT01124435 - Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients | Biotech Hunter | Biotech Hunter